A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLC
Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
This is an open label, non-randomised phase 1b/2 study including patients with non-small cell
lung cancer who have progressed after treatment with immune checkpoint inhibitors (anti
PD1/PDL1 with or without CTLA4 inhibitors) and platinum-based chemotherapy. The study
medications include nivolumab, an anti-PD1 inhibitor and ADG106, an agonist antibody of
4-1-BB.
The investigators hypothesize that the combination of nivolumab and ADG106 would be
tolerable, and demonstrate significant clinical anti-tumour activity in patients with NSCLC
that has failed antiPD1/antiPDL1 immunotherapy and standard platinum-based chemotherapy. The
investigators propose to conduct a phase 1b/2 study to investigate this strategy.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
National University Hospital, Singapore
Collaborators:
Adagene Inc Bristol-Myers Squibb Singapore Translational Cancer Consortium